JT Stratford LLC Has $11.05 Million Holdings in Johnson & Johnson $JNJ

JT Stratford LLC raised its holdings in Johnson & Johnson (NYSE:JNJ) by 7.6% during the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 59,577 shares of the company’s stock after buying an additional 4,216 shares during the period. Johnson & Johnson comprises approximately 1.5% of JT Stratford LLC’s investment portfolio, making the stock its 16th biggest holding. JT Stratford LLC’s holdings in Johnson & Johnson were worth $11,047,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently made changes to their positions in the business. Abich Financial Wealth Management LLC bought a new position in Johnson & Johnson during the third quarter worth $26,000. Evolution Wealth Management Inc. bought a new stake in shares of Johnson & Johnson during the 2nd quarter worth about $27,000. Clayton Financial Group LLC bought a new stake in shares of Johnson & Johnson during the 3rd quarter worth about $28,000. Semmax Financial Advisors Inc. raised its holdings in Johnson & Johnson by 55.0% in the 2nd quarter. Semmax Financial Advisors Inc. now owns 203 shares of the company’s stock valued at $31,000 after acquiring an additional 72 shares during the period. Finally, Compass Financial Services Inc lifted its position in Johnson & Johnson by 707.1% during the third quarter. Compass Financial Services Inc now owns 226 shares of the company’s stock worth $42,000 after acquiring an additional 198 shares during the last quarter. 69.55% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

Several equities analysts have recently commented on the company. Loop Capital set a $220.00 target price on Johnson & Johnson in a research report on Tuesday, January 27th. BMO Capital Markets reaffirmed an “outperform” rating on shares of Johnson & Johnson in a report on Thursday, December 11th. Barclays lifted their target price on Johnson & Johnson from $197.00 to $217.00 and gave the stock an “equal weight” rating in a report on Tuesday, December 30th. Sanford C. Bernstein raised their price target on shares of Johnson & Johnson from $208.00 to $225.00 and gave the stock a “market perform” rating in a research report on Friday, January 23rd. Finally, Wall Street Zen downgraded shares of Johnson & Johnson from a “buy” rating to a “hold” rating in a report on Saturday, February 14th. One analyst has rated the stock with a Strong Buy rating, seventeen have given a Buy rating and nine have issued a Hold rating to the stock. According to data from MarketBeat.com, Johnson & Johnson has a consensus rating of “Moderate Buy” and an average price target of $232.70.

Johnson & Johnson Trading Down 0.6%

Shares of JNJ opened at $245.28 on Thursday. The company has a debt-to-equity ratio of 0.48, a quick ratio of 0.77 and a current ratio of 1.03. Johnson & Johnson has a 52-week low of $141.50 and a 52-week high of $251.71. The firm has a market cap of $591.10 billion, a price-to-earnings ratio of 22.20, a PEG ratio of 2.44 and a beta of 0.34. The business’s fifty day moving average is $227.06 and its 200-day moving average is $203.31.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings data on Saturday, January 31st. The company reported $2.46 earnings per share for the quarter. Johnson & Johnson had a return on equity of 33.04% and a net margin of 28.46%.The business had revenue of $24.28 billion for the quarter. Equities analysts anticipate that Johnson & Johnson will post 10.58 EPS for the current fiscal year.

Johnson & Johnson Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 10th. Investors of record on Tuesday, February 24th will be given a dividend of $1.30 per share. This represents a $5.20 dividend on an annualized basis and a yield of 2.1%. The ex-dividend date is Tuesday, February 24th. Johnson & Johnson’s dividend payout ratio is currently 47.06%.

Key Stories Impacting Johnson & Johnson

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: FDA Fast Track for nipocalimab in systemic lupus erythematosus — The drug earned Fast Track designation supported by positive Phase 2 data and an ongoing Phase 3 study, which can accelerate review timelines and boosts the pharma pipeline narrative. Nipocalimab Fast Track PR
• Positive Sentiment: New direct-to-consumer drug sales channel — J&J launched a U.S. website to sell certain medications directly to uninsured or out-of-pocket patients, which may expand access and create a new revenue stream outside traditional pharmacy channels. Reuters: Direct-to-consumer site
• Neutral Sentiment: Oncology and other late-stage programs showing progress — Early pasritamig data and other oncology moves underpin higher long-term estimates, but timelines and commercial execution remain key variables. Yahoo: Pipeline & legal update
• Neutral Sentiment: Investor access and upcoming results — J&J scheduled its first-quarter results call for April 14; the call and Q1 metrics will be the next catalysts for guidance and near-term sentiment. Earnings call notice
• Neutral Sentiment: Dividend and income investor interest — J&J continues to be highlighted among top dividend/dividend-growth picks, supporting demand from income-focused investors even amid broader volatility. Dividend aristocrat piece
• Neutral Sentiment: Analyst stance: Hold with limited upside — Bank of America reiterated a Hold rating citing higher oncology-driven estimates but constrained upside, which may temper upside momentum despite pipeline wins. TipRanks: Hold rating
• Negative Sentiment: Bayer legal challenge over prostate cancer product claims — Bayer has initiated legal action related to prostate cancer product claims, introducing litigation risk and potential costs or reputational impact that investors dislike. Yahoo: Legal challenge mention

Insider Activity at Johnson & Johnson

In related news, EVP Vanessa Broadhurst sold 6,197 shares of the stock in a transaction that occurred on Tuesday, February 17th. The shares were sold at an average price of $243.39, for a total value of $1,508,287.83. Following the completion of the transaction, the executive vice president owned 23,003 shares of the company’s stock, valued at $5,598,700.17. This represents a 21.22% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, EVP Timothy Schmid sold 22,623 shares of the business’s stock in a transaction on Wednesday, February 18th. The stock was sold at an average price of $244.33, for a total transaction of $5,527,477.59. Following the sale, the executive vice president directly owned 26,769 shares in the company, valued at approximately $6,540,469.77. The trade was a 45.80% decrease in their position. The SEC filing for this sale provides additional information. In the last three months, insiders sold 30,142 shares of company stock valued at $7,360,528. 0.16% of the stock is owned by insiders.

About Johnson & Johnson

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.